ImClone Systems And ImClone Systems Release: FDA Approves ERBITUX(R) For Treatment Of Head And Neck Cancer; First And Only Approved Monoclonal Antibody For Squamous Cell Carcinoma Of The Head And Neck

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--March 1, 2006--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved ERBITUX(R) (Cetuximab), an IgG1 monoclonal antibody, for use in the treatment of squamous cell carcinoma of the head and neck. Designed to inhibit the function of the epidermal growth factor receptor (EGFR) - a molecular structure linked to tumor growth - ERBITUX is the first and only monoclonal antibody to be approved for the treatment of head and neck cancer.

Back to news